Additional InformationTHE PHARMACEUTICAL MARKET: INDIA - REVIEW
The Indian pharmaceutical market is highly competitive and remains dominated by low-priced, domestically-produced generics. Despite having the second largest population in the world and a growing middle class with high healthcare expectations, India accounts for less than 2% of the world pharmaceutical market in value terms. In one of the world's better performing economies, spending on pharmaceuticals accounts for less than 1% of GDP and average per capita spending remains one of the lowest levels in the region.
India’s biopharmaceutical sector is currently experiencing double digit growth and this is expected to continue, driven by the vaccines market. Growth drivers include education and increased awareness of disease prevention, increases in disposable income and government participation in immunisation programmes. Continued growth is also expected in the diagnostic and therapeutic segments, including cancer and diabetes. India is already known as the diabetes capital of the world and the number of diabetes patients in India is expected to grow to 70 million by 2025. Cancer therapies are also lucrative for many Indian companies due to high unmet need, increased awareness and the comparative affordability of domestically produced drugs.
The Indian pharmaceutical industry is responsible for around 10% of world pharmaceutical production. Over the last few years, a number of Indian pharmaceutical companies have been targeted for foreign acquisition. Concerns have been raised that this trend could adversely affect generic drug prices in India. The Ministry of Health wants safeguards built into the Foreign Direct Investment process amid fears that continued foreign acquisitions will adversely affect the domestic industry and push prices up, thereby potentially undermining the government’s efforts to make generic drugs affordable. This could lead to essential medicines becoming more expensive and adversely affecting public health programmes.
The need to maintain low prices for essential medicines has been addressed in the government’s draft National Pharmaceutical Pricing Policy (NPPP), released in 2011. The proposed NPPP focuses on the National List of Essential Medicines (NLEM), which is periodically revised. The headline major change is a move from the principle of cost-based pricing to a market-based pricing model. The Department of Pharmaceuticals argues that market-based pricing would result in more transparent and fair pricing, as well as increasing competition in the marketplace. Price regulation will encompass all drugs listed in the NLEM, as well as formulations containing combinations of drugs listed in the NLEM; this will include combinations comprising listed drugs and unlisted drugs. If the NPPP is implemented, around 60% of the drugs currently available in India will come under price control.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Pharmaceutical Market Hong Kong
Pharmaceutical Market Indonesia
HIGHLY DETAILED REPORT CONTENT
Including Espicom's at a glance strategic analysis and key data projections
Political, economic, legal and demographic analysis
Disease burden and prevalence
Organisation, expenditure, infrastructure, services and workforce
Regulatory developments and marketing registration/authorisation
PRICING & REIMBURSEMENT
Projections, product development, manufacturing and trade
Trade associations, trade fairs, company intelligence and competitive strategies
BIOLOGICS & BIOSIMILARS
OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis
METHODOLOGY & SOURCES
More Prescription Drugs reports by Espicom Healthcare Intelligence
Understanding the US's Regional Healthcare Markets by Espicom Healthcare Intelligence
Understanding the US's Regional Healthcare Markets
For years to come, the US healthcare market will remain the most attractive to providers of medical services. Considerable ...
The Pharmaceutical Market: Brazil by Espicom Healthcare Intelligence
The Pharmaceutical Market: Brazil
OVERVIEW OF THE PHARMACEUTICAL MARKET IN BRAZIL The Brazilian pharmaceutical market remains our favourite regional market in Latin America due to ...
Inhalation & Nasal Spray Generic Drugs 2013 by Espicom Healthcare Intelligence
Inhalation & Nasal Spray Generic Drugs 2013
Around three quarters of the US$36.4 billion respiratory prescription drugs market comprises drugs that are delivered using inhalation ...
See all reports like this >>
Middle East North Africa Pharmaceutical Market Forecasts to 2018 by Espicom Healthcare Intelligence
Middle East North Africa Pharmaceutical Market Forecasts to 2018
The global pharmaceutical market is forecast to be worth over US$1,250 billion by 2018 - but ...
More India Prescription Drugs reports
Databook Q1 2014: India Digital Advertising Spend - Pharmaceutical & Healthcare Industry by Socintel360
Databook Q1 2014: India Digital Advertising Spend in Pharmaceutical & Healthcare IndustryOnline advertising spend by pharmaceutical & healthcare brands in India stood at US$18 million ...
Pharmaceuticals and Healthcare Report - India Q3 2014 by Business Monitor International
India Pharmaceuticals and Healthcare Report Q3 2014BMI View: The Pharmaceutical Research and Manufacturers of America (PhRMA)'s decision to list Indiaas a Priority Foreign Country illustrates ...
Pharmaceuticals: BRIC (Brazil, Russia, India, China) Industry Guide by MarketLine
Pharmaceuticals: BRIC (Brazil, Russia, India, China) Industry GuideIntroductionThe BRIC Pharmaceuticals industry guide provides top-line qualitative and quantitative summary information including: market size (value 2009-13, and ...
See all reports like this >>
India Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
India Pharmaceuticals and Healthcare Report Q2 2014BMI View: Pharmaceutical firms in India are reporting improved performance for the quarterended December 2013. This is an early ...
More India reports
D&B Country RiskLine Report: India by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
Spirits - BRIC (Brazil, Russia, India, China) Industry Guide by MarketLine
Spirits - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, China) ...
See all reports like this >>
Wine - BRIC (Brazil, Russia, India, China) Industry Guide by MarketLine
Datamonitor's Wine - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, ...